Monitor for any future 8-K filings regarding DeFloria's Phase 2 trial progress or financing, as Charlotte's Web's equity stake in DeFloria represents a potential catalyst. No immediate trading action warranted based on this board transition alone.
Price Chart
Executive Summary
Co-founder Jared Stanley resigned from the Board of Directors effective June 3, 2026, to focus full-time on his role as CEO of DeFloria, a clinical-stage affiliate developing a Phase 2 botanical drug for autism-related irritability. The departure is amicable and supported by management, with Stanley remaining in an advisory capacity and Charlotte's Web retaining its shareholder stake in DeFloria. This is a routine board transition with no financial impact or disagreement disclosed.
Key Facts
- Co-founder Jared Stanley resigned from the Board of Directors effective June 3, 2026.
- Stanley will continue as CEO of DeFloria, a clinical-stage affiliate developing AJA001 for autism-related irritability.
- Stanley will remain in an advisory capacity to Charlotte's Web.
- The resignation is not related to any disagreement with the company, management, or board.
- Board size reduces to six directors following the departure.
- Charlotte's Web remains a co-founder and shareholder in DeFloria.
Financial Impact
No financial figures disclosed; no material impact expected.
Risk Factors
- Loss of co-founder board presence could reduce strategic oversight of cultivation and regulatory initiatives.
- DeFloria's clinical-stage pipeline carries inherent development and regulatory risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001750155-26-000097 |
| Document: cweb_jun5x2026jaredstanley.htm | 0001750155-26-000097 |
| Document: 0001750155-26-000097-index-headers.html | 0001750155-26-000097 |
| Document: 0001750155-26-000097-index.html | 0001750155-26-000097 |
| Document: 0001750155-26-000097.txt | 0001750155-26-000097 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 9w ago | 8-K | $0.3320 | awaiting T+60 | — | $0.2668 (−19.64%) |
Jun 5, 2026 20w ago | 8-K | $0.4200 $0.3110 | ▼ −25.95% | ▼ −29.27% | $0.2668 (−36.48%) |
Jun 3, 2026 20w ago | 8-K | $0.4170 $0.3052 | ▼ −26.81% | ▼ −28.69% | $0.2668 (−36.02%) |
Jun 1, 2026 21w ago | 8-K | $0.4910 $0.3310 | ▼ −32.59% | ▼ −33.70% | $0.2668 (−45.66%) |
May 13, 2026 23w ago | 8-K | $0.4860 $0.2520 | ▲ +48.15% | ▲ +52.59% | $0.2668 (+45.10%) |
Apr 16, 2026 27w ago | DEFA14A | $0.6080 $0.2681 | ▼ −55.90% | ▼ −62.95% | $0.2668 (−56.12%) |
Mar 31, 2026 30w ago | 8-K | $0.7350 $0.3300 | ▼ −55.10% | ▼ −67.48% | $0.2668 (−63.70%) |
Mar 31, 2026 30w ago | DEFA14A | $0.7350 $0.3300 | ▼ −55.10% | ▼ −67.48% | $0.2668 (−63.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers